To include your compound in the COVID-19 Resource Center, submit it here.

AbbVie's upadacitinib meets in second Phase III for RA

AbbVie Inc. (NYSE: ABBV) reported top-line data from the Phase III SELECT-BEYOND trial in 498 patients with moderate to severe rheumatoid arthritis showing that both doses of oral upadacitinib (ABT-494) met the two primary endpoints vs. placebo. On the first primary

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE